Head-To-Head Contrast: Absci (NASDAQ:ABSI) and Regeneron Pharmaceuticals (NASDAQ:REGN)

Regeneron Pharmaceuticals (NASDAQ:REGN) and Absci (NASDAQ:ABSI) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, earnings, dividends and risk.

Profitability

This table compares Regeneron Pharmaceuticals and Absci’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Regeneron Pharmaceuticals	27.86%	13.47%	10.34%
Absci	-7,756.38%	-61.71%	-54.52%

Valuation and Earnings

This table compares Regeneron Pharmaceuticals and Absci”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Regeneron Pharmaceuticals	$14.34 billion	5.88	$4.50 billion	$40.46	20.24
Absci	$2.80 million	741.60	-$115.18 million	($0.80)	-15.12

Regeneron Pharmaceuticals has higher revenue and earnings than Absci. Absci is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

83.3% of Regeneron Pharmaceuticals shares are owned by institutional investors. Comparatively, 52.0% of Absci shares are owned by institutional investors. 7.0% of Regeneron Pharmaceuticals shares are owned by insiders. Comparatively, 10.5% of Absci shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Regeneron Pharmaceuticals and Absci, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Regeneron Pharmaceuticals	0	8	22	1	2.77
Absci	1	0	11	0	2.83

Regeneron Pharmaceuticals currently has a consensus target price of $847.90, indicating a potential upside of 3.56%. Absci has a consensus target price of $14.50, indicating a potential upside of 19.83%. Given Absci’s stronger consensus rating and higher possible upside, analysts plainly believe Absci is more favorable than Regeneron Pharmaceuticals.

Volatility & Risk

Regeneron Pharmaceuticals has a beta of 0.16, indicating that its share price is 84% less volatile than the S&P 500. Comparatively, Absci has a beta of 2.27, indicating that its share price is 127% more volatile than the S&P 500.

Summary

Regeneron Pharmaceuticals beats Absci on 10 of the 15 factors compared between the two stocks.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

About Absci

Absci Corporation operates as a data-first generative artificial intelligence (AI) drug creation company in the United States. The company combines AI with scalable wet lab technologies to create biologics for patients. Its integrated drug creation platform is designed to improve upon traditional biologic drug discovery by using AI to simultaneously optimize multiple drug characteristics that may be important to development and therapeutic benefit. The company was founded in 2011 and is headquartered in Vancouver, Washington.